Liu Yunyue, Wen Liang, Jiang Lingjie, Xu Jia, Meng Yuanguang, Yang Wen
Department of Obstetrics and Gynecology, The Seventh Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Chinese People's Liberation Army (PLA) Medical School, Beijing, China.
Transl Cancer Res. 2025 May 30;14(5):3201-3211. doi: 10.21037/tcr-2025-802. Epub 2025 May 27.
Cervical cancer remains a significant global health concern, necessitating effective screening strategies. Traditional methods, such as liquid-based cytology (LBC) and high-risk human papillomavirus (HR-HPV) testing, have limitations in sensitivity and specificity. This study aimed to evaluate the diagnostic performance of p16, Ki-67, and minichromosome maintenance protein 2 (MCM2) as biomarkers in cervical cancer screening, both as standalone methods and in combination, to improve early detection and risk stratification.
This prospective study included 344 women who underwent LBC and HR-HPV testing, followed by the gold standard of colposcopy and biopsy. Immunocytochemical (ICC) staining for p16, Ki-67, and MCM2 was performed. The sensitivity, specificity, and Youden index were calculated to compare the efficacy of the single and combined screening methods.
LBC alone demonstrated suboptimal sensitivity, while HR-HPV testing exhibited low specificity. Among the single methods, dual staining of p16 paired with MCM2 (p16/MCM2) when using a high-risk threshold achieved the highest Youden index (0.55). The combination of LBC with p16/MCM2 yielded superior sensitivity (96.3%) and moderate specificity (42.6%), outperforming the combination of HR-HPV with dual staining of p16/MCM2. Importantly, all missed diagnoses were high-grade squamous intraepithelial lesion (HSIL) with cervical intraepithelial neoplasia (CIN) grades 2-3, and no cases of cervical cancer were missed.
HR-HPV-based primary screening with p16/Ki-67 triage may offer a viable strategy for cervical cancer detection. Combining LBC with p16/MCM2 dual staining demonstrated improved sensitivity and specificity compared to conventional methods. Notably, p16/MCM2 as a standalone assay achieved the highest Youden index when using a high-risk threshold. Further validation through multicenter studies is essential to confirm its generalizability.
宫颈癌仍然是一个重大的全球健康问题,需要有效的筛查策略。传统方法,如液基细胞学检查(LBC)和高危型人乳头瘤病毒(HR-HPV)检测,在敏感性和特异性方面存在局限性。本研究旨在评估p16、Ki-67和微小染色体维持蛋白2(MCM2)作为生物标志物在宫颈癌筛查中的诊断性能,包括单独使用和联合使用,以改善早期检测和风险分层。
这项前瞻性研究纳入了344名接受LBC和HR-HPV检测的女性,随后进行了阴道镜检查和活检的金标准检查。对p16、Ki-67和MCM2进行免疫细胞化学(ICC)染色。计算敏感性、特异性和尤登指数,以比较单一和联合筛查方法的效果。
单独的LBC显示出不理想的敏感性,而HR-HPV检测的特异性较低。在单一方法中,当使用高危阈值时,p16与MCM2的双重染色(p16/MCM2)获得了最高的尤登指数(0.55)。LBC与p16/MCM2的联合使用产生了更高的敏感性(96.3%)和中等特异性(42.6%),优于HR-HPV与p16/MCM2双重染色的联合使用。重要的是,所有漏诊病例均为高级别鳞状上皮内病变(HSIL)伴宫颈上皮内瘤变(CIN)2-3级,未漏诊宫颈癌病例。
基于HR-HPV的初筛结合p16/Ki-67分流可能为宫颈癌检测提供一种可行的策略。与传统方法相比,LBC与p16/MCM2双重染色相结合显示出更高的敏感性和特异性。值得注意的是,p16/MCM2作为一种单独的检测方法,在使用高危阈值时获得了最高的尤登指数。通过多中心研究进行进一步验证对于确认其普遍性至关重要。